**Novartis: A Pioneer in Innovative Medicine** Novartis is a multinational pharmaceutical giant that has been redefining the boundaries of medicine for over two decades. Formed in March 1996 through the merger of Ciba-Geigy and Sandoz Laboratories, Novartis has a rich history that spans over 250 years, tracing back to its predecessor companies[3][7]. **History and Evolution** Novartis was created to focus on pharmaceuticals and agrochemicals, eventually spinning off its agribusiness to form Syngenta[1][3]. The company has continuously transformed itself, shifting from a broad health company to a focused drug developer. Key milestones include the introduction of groundbreaking drugs like Entresto for heart failure and Kymriah for leukemia[1]. **Key Achievements** Novartis has been instrumental in developing life-changing medications. Notable achievements include the discovery of DDT by Paul Hermann Müller at Geigy, which saved millions of lives, and the development of LSD by Sandoz, initially used as a psychiatric drug[2]. Recent innovations include Cosentyx for psoriasis and psoriatic arthritis[1]. **Current Status** Today, Novartis is an innovative medicines company dedicated to improving and extending lives. It serves 296 million people worldwide with its medicines[4]. The company continues to invest in cutting-edge technologies and research, focusing on cancer, heart disease, and inflammatory conditions[6]. **Notable Aspects** Novartis is recognized for its strategic acquisitions, such as AveXis for gene therapy and Fougera Pharmaceuticals for skin care[3]. Despite facing challenges, including patent disputes and legal issues, Novartis remains a leader in the pharmaceutical industry, committed to advancing medical science[3]. Its global research network and partnerships with leading institutions underscore its commitment to innovation and patient care[1].